Jane S. Ricciuti, RPh, MS


April 22, 2003

In This Article

Cardiovascular Agents


Manufacturer: GlaxoSmithKline

Drug Approval Classification: Supplemental New Drug Application (Approval Date: 03/28/03)

New Indication: Coreg (carvedilol) is indicated for the treatment of patients with left ventricular dysfunction following myocardial infarction.

Coreg is also indicated for the treatment of essential hypertension.

Clinical Summary: CAPRICORN (CArvedilol Post InfaRction SurvIval COntRol in Left Ventricular DysfunctioN) trial -- a multinational, multicenter, randomized, double-blind, parallel group study in patients with left ventricular systolic dysfunction following a recent acute myocardial infarction -- evaluated the efficacy of carvedilol. A total of 1949 patients were randomized to carvedilol 6.25 mg twice daily or placebo and followed for a mean of 15 months. Ninety-eight percent of patients on study took an angiotensin II converting enzyme inhibitor. The risk of death was 23% lower for patients on carvedilol compared with placebo.

Coreg (carvedilol) Letter

Coreg (carvedilol)


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.